Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Insmed Incorporated: Clinical Trials & FDA Approval Profile

Insmed Incorporated (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (4 recruiting now), 9 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.5%
Median Closed Enrollment vs National (145 pts)95 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Insmed Incorporated
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)5 (4)
Completed vs Stopped Early9 / 2 (12.5%)
Median Closed Actual Enrollment95 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Insmed Incorporated Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI